Kidney Cancer Research Bureau currently conducts 6 trials sponsored by the N.N. Blokhin Russian Cancer Research Center, other federal agencies, funds, and private industry. Each clinical study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease. Every clinical trial has a protocol, or action plan, for conducting the trial. The plan describes what will be done in the study, how it will be conducted, and why each part of the study is necessary. We are discussing our protocols and concept sheets with leading oncologists (specialists in kidney cancer) before start. In the Russian Federation, an independent ethical committee must approve and monitor the protocol. They make sure that that the risks are small and are worth the potential benefits.
Moreover, some of our studies are basic and translation.
| Trials | Size | Status |
KCRB-002 basic research | 100 samples | Completed |
Phase II study of Low molecular weight heparin in combination with Interferon-alpha for treatment of metastatic renal cell carcinoma | 200 patients | Active, recruiting |
| Radiofrequency ablation instead of palliative nephrectomy in metastatic renal cell carcinoma patients with small primary tumor. | 40 vs.40 patients | Active, recruiting |
Independent review of sunitinib cancer-specific survival for metastatic renal cell carcinoma in Russia and C.I.S.
| 102 patients | Active |
Testosterone for RCC patients with bone metastases. Phase I/II study.
| 21 patients | Active, non recruiting |
| Phase II trial of Capecitabine and Interferon-alpha after Interleukine-2 regimens in MRCC patients. | 48 patients | Completed |
Date: 22 February 2009
If you would like to become a SPONSOR, click >> We need!